Advanced Biotechnologies Inc Releases Dengue-1 Purified Viral Lysate to Diagnose Infections; Useful Tool to Combat Epidemics

ABI’s Dengue-1 Purified Viral Lysate allows investigators to detect primary and secondary infections of Dengue-1 by immunoassays.  Epidemics of Dengue fever spread across the world while vaccines are still under development.

Columbia, Maryland - October 14, 2009 - Advanced Biotechnologies Inc (ABI) has released Dengue-1 Purified Viral Lysate for use in detecting primary and secondary infections of Dengue virus by ELISA and dot blot immunoassays of human plasma/serum.

Dengue fever epidemics have been reported in tropical and subtropical regions of the world, but is also spreading to a greater territory.  Dengue fever has been reported in over 100 countries, including the United States, where it has been found in Texas and Hawaii.  Clinical trials for vaccines against Dengue fever are still ongoing.

Dengue-1 purified virus (prior to lysis) was identified by visualization under Transmission Electron Microscopy (TEM), hemagglutination assay (HA), and immunofluorescence assay (IFA).  The product was tested by ELISA with Dengue IgG positive and negative human plasma.

About Advanced Biotechnologies Inc (ABI):

Since 1982, ABI has produced and supplied innovative virology products and services to researchers and manufacturers worldwide.  ABI offers a wide range of standard and custom products and services, including large-scale in vitro production of HIV and other viruses.  For more information about ABI’s capabilities, visit www.abionline.com.

For more information about ABI or Dengue-1 Purified Viral Lysate (catalog number 10-272-000), please contact:

Vanessa Jorgensen, Account Representative
Advanced Biotechnologies Inc
9108 Guilford Road
Columbia MD 21046-2701
800-426-0764 International: 410-792-9779
vjorgensen@abionline.com